. "approved"@en . "Take without regard to meals."@en . "Phenylpropanolaminum"@en . . . . . . . . . . . " "@en . "Norephedrin"@en . "Phenylpropanolamin"@en . . . . . . . "Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect."@en . . . . . . "14838-15-4"@en . . . . . . . "Norephedrine"@en . . . . "May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD₅₀=1490mg/kg (orally in rat)"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . . . . . "Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver."@en . . . . . . . . "Fenilpropanolamina"@en . . " "@en . . . . . . "For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity."@en . . . . . . . . . . . . . . . . . . . . . . . . "\u03B2-hydroxyamphetamine)"@en . . . . . . . . . . . . . . . "Limit caffeine intake."@en . "Phenylpropanolamine"@en . "2.1 to 3.4 hours."@en . . . . . "Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug."@en . . . "withdrawn"@en . . . . . . . . . . . . . . . "PPA"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Ph\u00E9nylpropanolamine"@en . . . . . . . . . . . . . . . . . . "2-amino-1-phenylpropan-1-ol"@en . .